Brian Hill
Overview
Explore the profile of Brian Hill including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
70
Citations
960
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Landsburg D, Frigault M, Heim M, Foley S, Hill B, Schofield G, et al.
J Immunother Cancer
. 2025 Feb;
13(2).
PMID: 39924174
Background: Tisagenlecleucel, a CD19 chimeric antigen receptor T-cell therapy, is approved for adults with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBCL) after ≥2...
2.
Di Staso R, Casadei B, Locke F, Jain M, Voorhees T, Kittai A, et al.
Blood Cancer J
. 2024 Nov;
14(1):197.
PMID: 39511146
No abstract available.
3.
4.
Park J, Nguyen T, Park S, Hill B, Shadgan B, Gandjbakhche A
Bioengineering (Basel)
. 2024 Jul;
11(7).
PMID: 39061791
A two-stream convolutional neural network (TCNN) for breathing pattern classification has been devised for the continuous monitoring of patients with infectious respiratory diseases. The TCNN consists of a convolutional neural...
5.
Ferry J, Hill B, Hsi E
J Hematol Oncol
. 2024 Jul;
17(1):51.
PMID: 38978094
In 2022, two updated classification systems for lymphoid neoplasms were published by the World Health Organization (WHO Classification of Haematolymphoid Tumours, 5th edition, referred to hereafter as WHO-HAEM5) and the...
6.
Shadman M, Ahn K, Kaur M, Lekakis L, Beitinjaneh A, Iqbal M, et al.
Blood Cancer J
. 2024 Jul;
14(1):108.
PMID: 38977682
In patients with relapsed DLBCL in complete remission (CR), autologous hematopoietic cell transplantation (auto-HCT) and CAR-T therapy are both effective, but it is unknown which modality provides superior outcomes. We...
7.
Wang T, Ahn K, Shadman M, Kaur M, Ahmed N, Bacher U, et al.
Leukemia
. 2024 May;
38(7):1564-1569.
PMID: 38750138
CD19 CAR T-cell (CAR-T) therapy is commonly administered to patients with relapsed or refractory large B-cell lymphomas (LBCL), but salvage or bridging therapy can sometimes lead to a complete response...
8.
Wierda W, Brown J, Abramson J, Awan F, Bilgrami S, Bociek G, et al.
J Natl Compr Canc Netw
. 2024 Apr;
22(3):175-204.
PMID: 38626800
Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are essentially different manifestations of the same disease that are similarly managed. A number of molecular and cytogenetic variables with prognostic...
9.
Stuver R, Mian A, Brown S, Devlin S, Caimi P, Chinapen S, et al.
Am J Hematol
. 2024 Mar;
99(6):1180-1183.
PMID: 38526002
No abstract available.
10.
Samples L, Voutsinas J, Fakhri B, Khajavian S, Spurgeon S, Stephens D, et al.
Blood Adv
. 2024 Feb;
8(9):2085-2093.
PMID: 38315043
Although Bruton tyrosine kinase inhibitors (BTKis) are generally well tolerated and less toxic than chemotherapy alternatives used to treat lymphoid malignancies, BTKis like ibrutinib have the potential to cause new...